NEW YORK, January 7, 2014 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), PAREXEL International Corporation (NASDAQ: PRXL), PhotoMedex, Inc. (NASDAQ: PHMD), and Cell Therapeutics, Inc. (NASDAQ: CTIC). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
NPS Pharmaceuticals, Inc. Research Report
On January 2, 2014, NPS Pharmaceuticals, Inc. (NPS Pharmaceuticals) announced that it has initiated a global registration study of teduglutide in pediatric patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support. According to NPS Pharmaceuticals, the 12-week, open-label study evaluating teduglutide will be conducted at sites throughout US and Europe, and is expected to enroll up to 36 patients. Roger Garceau, MD, FAAP, Executive Vice President and Chief Medical Officer of NPS Pharmaceuticals, commented, "We are particularly proud to advance teduglutide in pediatric Short Bowel Syndrome, as it may bring us one step closer to fulfilling a significant unmet need among children across the globe who face a life burdened by this rare disease." Garceau added, "We look forward to reporting top line results following the completion of the study in late 2014 or early 2015." The Full Research Report on NPS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Oramed Pharmaceuticals Inc. Research Report
On January 2, 2014, Oramed Pharmaceuticals Inc. (Oramed) announced that it has received Notices of Allowance from the Israel and Australian Patent Offices for "Methods and Compositions for Oral Administrations of Proteins." Oramed reported that the patent covers a core concept of platform technology in oral delivery of proteins which are currently delivered through injection. The Company stated that the allowance in Israel marks the second from the Israel Patent Office in the past 30 days and the second Australian patent allowance since the grant of a different patent in May 2012. Oramed further informed that the said patent has also been approved in Japan, China, Russia, and New Zealand. The Full Research Report on Oramed Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
PAREXEL International Corporation Research Report
On January 2, 2014, PAREXEL International Corporation (PAREXEL) announced that it will release its Q2 FY 2014 results after the stock market close on Wednesday, January 29, 2014. PAREXEL reported that the conference call and live webcast will be held on Thursday, January 30, 2013 at 10:00 a.m. ET. The Company further noted that the live webcast and replay will be accessible through the Investors menu on its website for one year. The Full Research Report on PAREXEL International Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
PhotoMedex, Inc. Research Report
On January 2, 2014, PhotoMedex, Inc. (PhotoMedex) revised its Q4 2013 revenue guidance, expecting revenues to be more than $60 million without any contribution from Japan, compared with prior guidance of more than $55 million without any contribution from Japan. According to PhotoMedex, the Q4 2013 revenue outperformance is primarily attributable to holiday advertising in the Consumer business segment that yielded global direct response sales above prior forecasts, and also to better-than-expected sales to retail and home shopping channel customers. Dr. Dolev Rafaeli, CEO of PhotoMedex, said, "Consumer demand for no!no! is strong and our advertising spend for the new no!no! Pro during the Christmas holiday season generated a very high media efficiency ratio. In other positive developments, we are experiencing strong patient response to our XTRAC advertising campaign in major markets. We are pleased that for the fourth consecutive quarter XTRAC treatment revenues grew by more than 50% over the prior-year comparison, and for the 12 months ended December 31, 2013 grew by more than 80% over the prior year." PhotoMedex noted that intends to release its Q4 2013 results in mid-March 2014. The Full Research Report on PhotoMedex, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Cell Therapeutics, Inc. Research Report
On January 2, 2014, Cell Therapeutics, Inc. (Cell Therapeutics) received a notification from the US Food and Drug Administration (FDA), which notifies that the partial clinical hold on tosedostat (IND 075503) has been removed and all ongoing studies may continue. According to Cell Therapeutics, Tosedostat is currently being studied in the US and European Union in investigator-sponsored and cooperative group-sponsored Phase 2 trials in elderly patients with newly diagnosed and relapsed acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). "We are pleased that the FDA has responded favorably to the tosedostat clinical trial data provided and removed the partial clinical hold to allow further development of tosedostat in ongoing and future studies," commented John Pagel, MD, PhD, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center; Associate Professor, Medical Oncology Division, University of Washington School of Medicine; and Principal Investigator in the tosedostat first-line AML/MDS trial. The Full Research Report on Cell Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
|SOURCE Analysts' Corner|
Copyright©2012 PR Newswire.
All rights reserved